Newsroom

Press Releases

See All

09/14/2021

Sarepta Therapeutics to Showcase Data from its Gene Therapy and RNA Platforms at World Muscle Society 2021 Virtual Congress
09/07/2021

Sarepta Therapeutics to Present at Upcoming Investor Conferences
09/07/2021

Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program

News Features

09/20/2021

Seroprevalence: What patients should know about pre-existing antibodies to gene therapy
08/26/2021

Measurements Used in Clinical Trials for Duchenne Muscular Dystrophy – an Overview
01/13/2021

How a collaboration in the lab led to a seat at the table in Sarepta’s Gene Editing Innovation Center
12/18/2020

Giving Thanks for Our Employees’ Incredible Dedication: Six Employees Explain Why Sarepta is a Top Place to Work
10/14/2020

Welcome to GT‐FAQ!
09/29/2020

Expanding Access to Newborn Screening for Those with Rare Diseases

Media Library

View All Media Library

Sarepta Corporate Logo

Sarepta Building Exterior thumbnail

Sarepta Building Exterior

LGMD Fact sheet thumbnail

LGMD Fact Sheet

NSAA Fact Sheet Thumbnail

NSAA Fact Sheet

Press Contact

Tracy Sorrentino
Executive Director, Public Relations
Sarepta Therapeutics, Inc.
[email protected]
617-274-4052